JPMorgan Chase & Co. Increases GSK (LON:GSK) Price Target to GBX 1,660

GSK (LON:GSK) had its price objective raised by equities researchers at JPMorgan Chase & Co. from GBX 1,530 ($19.22) to GBX 1,660 ($20.85) in a research note issued to investors on Thursday, Digital Look reports. The firm presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price target points to a potential downside of 3.96% from the stock’s previous close.

A number of other analysts have also recently commented on the stock. Barclays restated an “equal weight” rating and issued a GBX 1,725 ($21.67) price objective on shares of GSK in a research report on Monday, April 8th. Shore Capital reiterated a “buy” rating on shares of GSK in a report on Wednesday. Berenberg Bank upped their target price on shares of GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the stock a “buy” rating in a research note on Wednesday, February 14th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 1,950 ($24.49) target price on shares of GSK in a report on Wednesday, April 17th. One analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, GSK presently has an average rating of “Hold” and an average target price of GBX 1,675.63 ($21.05).

GSK Trading Up 1.4 %

Shares of GSK traded up GBX 23.50 ($0.30) on Thursday, reaching GBX 1,728.50 ($21.71). 9,500,043 shares of the company’s stock were exchanged, compared to its average volume of 6,958,847. The business has a 50 day moving average price of GBX 1,660.86 and a two-hundred day moving average price of GBX 1,555.08. The company has a current ratio of 0.88, a quick ratio of 0.73 and a debt-to-equity ratio of 140.82. The stock has a market capitalization of £70.70 billion, a P/E ratio of 1,438.33, a price-to-earnings-growth ratio of 1.12 and a beta of 0.27. GSK has a 12 month low of GBX 1,302.60 ($16.36) and a 12 month high of GBX 1,739.56 ($21.85).

Insider Transactions at GSK

In other GSK news, insider Urs Rohner purchased 434 shares of the business’s stock in a transaction dated Wednesday, March 20th. The shares were bought at an average price of GBX 1,662 ($20.88) per share, for a total transaction of £7,213.08 ($9,060.52). In other news, insider Urs Rohner bought 434 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The shares were acquired at an average price of GBX 1,662 ($20.88) per share, for a total transaction of £7,213.08 ($9,060.52). Also, insider Emma Walmsley sold 139,792 shares of GSK stock in a transaction on Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.83), for a total transaction of £2,317,751.36 ($2,911,382.19). Company insiders own 1.77% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.